Navigation Links
Scott & White Healthcare researcher finds success with new anti-cancer drug
Date:12/22/2009

A study conducted at Scott & White Healthcare in Temple, Texas, found that a new drug stopped the growth of breast tumors in mice. This drug is unique in that it works both by stopping the cancer cells from growing and metastasizing to other organs, and by stimulating the immune system to destroy breast cancer cells and keeps them from coming back. This is the only drug that's able to work in both ways, while all other treatments work in one way or another. And, this research initiative not only involves physicians and biologists working together to bring treatments from the laboratory to the bedside, but a unique third component agriculturalists.

Researcher Alexzander Asea, Ph.D., the Effie and Wofford Cain Endowed Chair in Clinical Pathology, and division chief of investigative pathology at Scott & White Healthcare and the Texas A&M Health Science Center, said "we found that some of the mice were essentially cured."

"All anti-cancer drugs broadly fall into two categories; either directly killing cancer cells (often healthy cells as well), or vaccines that help sick patients by boosting the immune system to better fight off cancer. This new drug works both ways, as a vaccine by taking away the cancer cell ability to grow, multiply and spread to distant organs, and by educating the immune system to recognize the breast cancer cells as 'foreign invaders' that need to be attacked and destroyed and to continue that process over time," Dr. Asea said.

Dr. Asea went on to say "breast cancer cells fly under the radar of the immune system, by turning off the machinery that normally puts recognition structures on the surface of cancer cells which the immune system uses to recognize and destroy them. To overcome this problem, this injectable drug turns on this machinery within the cancer cells allowing the immune system to recognize the cancer cells and kill them. The unique thing is that the revved-up immune cells will continue patrolling for any hidden cancer cells months and years after the last cancer cells have been killed," Dr. Asea said.

"Collaborating with the agricultural community on this research also allows us to use a special delivery mechanism of the drug that doesn't cause the negative side effects you see with more traditional treatments like chemotherapeutic agents," explained Dr. Asea.

Dr. Asea said only about one year of additional work is required before Phase I clinical trials can begin in women with metastatic breast cancer at Scott & White Hospital. "However, this stage requires a significant amount of funding. We're currently looking at various sources including federal, state and private sources to get this promising drug to the patients who need it."


'/>"/>

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Source:Eurekalert

Related biology news :

1. American Society for Microbiology honors D. Scott Merrell
2. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
3. Phoenix conference highlights TGens and Scottsdale Healthcares contributions to molecular oncology
4. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
5. Wolf reintroduction proposed in Scottish Highland test case
6. Scott & White Healthcare researcher finds success with new anti-cancer drug
7. ESA honored at White House ceremony
8. Unveiling the underwater ways of the white shark
9. New whitepaper offers options for university implementation of NIH policy
10. Clumps of red and white blood cells may contribute to sickle cell disease
11. White House science office needs upgrade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... ... April 25, 2017 , ... ... Partners.     , Covalent’s Analytical Services unit provides high-quality data to clients, ... within 24 hours of receipt. There are no price premiums, and customers are ...
(Date:4/21/2017)... ... ... Having worked on the design of the innovative Triton™ lab bench ... design architects from around the country at the Lab Design Conference 2017 in Raleigh, ... Casey will be at the show, where they will highlight the unique elements of ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick ... a range of emerging technology-based businesses, recently earned a $77,518 grant from the ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... and clinical research community’s growing body of knowledge during its Eighth Annual ... Theatre and the adjacent Darling Atrium. During the event, undergraduates, graduate students, and ...
Breaking Biology Technology: